Industrializing allogeneic iPSC-derived cell therapies: challenges and solutions

Cynata CEO Dr Kilian Kelly and Chief Business Officer Dr Mathias Kroll examine the manufacturing challenges facing the iPSC-derived cell therapy field as the first products approach regulatory approval. The article identifies differentiation as the critical bottleneck in scaling iPSC-derived therapies. Manual, labour-intensive protocols performed in tissue culture flasks cannot meet demand for therapies requiring millions of doses globally. The authors break down the manufacturing pathway into five stages and explore emerging technological solutions: iPSC expansion (largely solved via 3D vessel technology), differentiation (requiring robotic automation), cell amplification (addressed by shear-stress-reducing bioreactors), fill & finish (high-throughput automated systems), and cryopreservation & distribution (ultra-low temperature logistics). The article draws on Cynata's experience developing manufacturing strategies for Cymerus™ MSCs targeting osteoarthritis, affecting over 600 million people globally.

Read article: https://tinyurl.com/44szaavz